In vivo and in vitro effects of atrial natriuretic peptide on renin release.
1. This study investigated the effect of atrial natriuretic peptide on renin release from the kidney. The in vitro direct effect was examined in the animal experiment using renal cortical slices of rat, and the in vivo effect was observed in the human infusion study. 2. In the in vitro experiments, alpha-human atrial natriuretic peptide (alpha-hANP) ranging 10(-9) to 10(-6) mol/L did not change the basal renin release rate from the renal cortical slices (-9% at 10(-6) mol/L, NS). Isoproterenol (10(-6) mol/L) increased renin release by 40% (P < 0.001), whereas angiotensin II (10(-6) mol/L) suppressed it by 48% (P < 0.001). However, alpha-hANP did not affect the stimulative effect of isoproterenol or the inhibitory effect of angiotensin II. 3. Also in the human study, infusion of 25 ng/kg per min alpha-hANP failed to change the plasma renin activity in normotensive subjects (-4%) or patients with essential hypertension (+5%), or even in patients with raised renin levels such as renovascular hypertension (+10%) or congestive heart failure (-13%). 4. These results put forth negative views on the direct involvement of atrial natriuretic peptide in renin release from the juxtaglomerular apparatus.
Ishimitsu
T
T
Second Department of Internal Medicine, University of Tokyo, Japan.
Hirata
Y
Y
Matsuoka
H
H
Ishii
M
M
Sugimoto
T
T
Kangawa
K
K
Matsuo
H
H
D000328:Adult; D000818:Animals; D009320:Atrial Natriuretic Factor / Q000494:pharmacology*; D001794:Blood Pressure / Q000187:drug effects; D005260:Female; D006333:Heart Failure / Q000201:enzymology*; D006801:Humans; D006973:Hypertension / Q000201:enzymology*; D006978:Hypertension, Renovascular / Q000201:enzymology; D066298:In Vitro Techniques; D007672:Kidney Cortex / Q000187:drug effects* / Q000201:enzymology; D008875:Middle Aged; D051381:Rats; D017207:Rats, Sprague-Dawley; D012083:Renin / Q000187:drug effects* / Q000378:metabolism
D009320:Atrial Natriuretic Factor; D012083:Renin